Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), explore potential future research directions in metastatic uveal melanoma.
Key Updates in Metastatic Uveal Melanoma From ESMO 2025
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), highlight current treatment approaches in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss the use of percutaneous hepatic perfusion in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), break down data from the phase 2 CHOPIN trial evaluating percutaneous hepatic perfusion plus nivolumab and ipilimumab in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss the potential clinical implications of the CHOPIN trial in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss other ways percutaneous hepatic perfusion could be integrated into metastatic uveal melanoma management.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), break down other data in metastatic uveal melanoma from the 2025 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5